- Home
- CYN vs AEON Comparison
CYN vs AEON Comparison
Compare CYN & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | AEON |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 62 | 8 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 25.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYN | AEON |
|---|---|---|
| Price | $1.42 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 273.8K | 69.9K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $0.53 |
| 52 Week High | $41.54 | $1.45 |
Technical Indicators
Market Signals| Indicator | CYN | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 36.62 |
| Support Level | $1.33 | $0.70 |
| Resistance Level | $1.76 | $0.83 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 22.02 | 26.82 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.